Is what you seeing truth?------Re-evaluate the consistency and variation of the data in gut microbiome
李后开
时长:20:33 分会场:2019中国肠道大会 - 中医药大会
Gut dysbiosis is a fundamental factor for various human diseases such as obesity, non-alcoholic fatty liver disease, diabetes mellitus, and even cancers. Tremendous publications on the relationship between gut microbiota and diseases are available during the past years in the context of advances of 16S rDNA-based bacteria sequencing technology. Notably, data of gut microbiome usually showed dramatic variation and poor consistency between different reports. Unfortunately, most scientists paid little attention to the authenticity of the 16S rDNA sequencing data provided by the third party. Actually, there are various ways for introducing disturbance on the variation and consistency of results during the whole process from sample collection to analysis. In this speech, I will take the obesity study for example to discuss the variation and inconsistency of previous publications, and provide some of our recent observations on the data consistency when different storages were used based on the 16S rDNA sequencing technology. Thus, we highlight the importance of re-evaluating the consistency and variation of the data in gut microbiome.
李后开
上海中医药大学交叉科学研究院
了解更多
更多视频
肠道菌群为探析中医药科学内涵开启一扇窗
以团队研究为基础进行交流:针对中医临床用药困惑,整合多学科策略和手段,揭示肠道菌介导的中药大分子与小分子协同作用机制,探讨肠道菌群在中医药科学内涵阐释中的重要性,为中医药的传承和创新转化研究提供新思路。
李松林 时长:30:06
中药降糖与肠道菌群
从今年来中医药在糖尿病的防治中取得的疗效为切入点,介绍了中医 药降糖的同时所看到的与之相关的肠道菌群结构的变化,重点介绍了 课题组完成的两项临床研究:葛根芩连汤与降糖调脂方的临床研究, 在降糖的同时菌群的一些变化,菌群与血糖更好地疗效预测作用。由 此,提出了未来的研究方向。
连凤梅 时长:20:40
基于肠道菌群的中药创新研究模式探讨
传统中药成份众多、配伍复杂,导致作用机理研究困难;同一方剂应用不同个体存在疗效及毒副作用差异,其分子机制也尚不明确。近年来研究表明,口服中药可调节人体肠道微生物的结构和功能,影响人体免疫、代谢及内分泌,进而影响人体健康;另一方面,人体肠道微生物能够产生不同的酶,催化水解、还原、裂解、官能团转移等药物代谢反应,直接参与宿主对药物的代谢吸收过程。因此,集成宏基因组、代谢组、微生物分离培养及体外发酵、实验动物等技术手段,研究单方及复方中药与肠道菌群在体内及体外的双向相互作用,建立中药与肠道菌群互作数据库,有助探讨中药作用机制、鉴定中药方剂效应靶点、明确方剂效应人群、优化中药配方设计、提升中医药疗效机制,并以肠道菌群为靶标,用新思路推动中药新药及健康产品开发。
韩丽娟 时长:32:11
评论